The purpose of this study is to determine whether levels of circulating endothelial progenitor cells (cEPC) are increased in the acute phase of ischemic stroke.
Endothelial dysfunction is a key component of atherosclerosis which contributes to the development of cardio- and cerebrovascular diseases. However, endothelial dysfunction (ED) is not established as a risk factor for ischemic stroke. As a novelty the proposed trial investigates the following variety of indirect markers of endothelial function in acute ischemic stroke: circulating endothelial progenitor cells (EPC), endothelial microparticles (EMP), ENDOPAT (RH- PAT ratio) in two regards: 1. time after ischemic events (\< 48h, Days 4-5, day 7 or at discharge) 2. etiological stroke subtypes It is not known whether these parameters are changed after acute cerebral ischemia and could possibly serve as specific target for treatment.
Study Type
OBSERVATIONAL
Enrollment
30
Center for Stroke Research Berlin
Berlin, State of Berlin, Germany
RECRUITINGLevels of cEPC
Levels of cEPC (CD34+/CD133+/VEGF2R+/CD31) in % of mononuclear cells using flow cytometry with respect to stroke subtypes.
Time frame: <48h, day 4-5, discharge or day 7
Levels of EMP
Levels of EMP (Annexin V+/CD31+; CD62E+) using flow cytometry with respect to stroke subtypes.
Time frame: <48h, day 4-5, day 7 or discharge
ENDOPAT
Digital pulse volume change (with RH PAT as non invasive measurement (PAT-ratio; ENDOPAT, Itamar Medical Ltd.) for non-invasive, peripheral endothelial function
Time frame: <48h, day 4-5,day 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.